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During the 10-year period (1980 to 1989), 76 patients with he-
patocellular carcinoma (HCC) were treated by subtotal hepatic 
resection (HX) and 105 patients by orthotopic liver transplan-
tation (TX) under cyclosporine-steroid therapy. Overall 1- to 5-
year survival rates ofthe HX group were 71.1%,55.0%,47.2%, 
37.2%, and 32.9%, respectively, and those ofthe TX group were 
65.7%,49.0%,39.2%,35.6%, and 35.6%, respectively. The sur-
vival rates after HX and after TX correlated well with pTNM 
stages and were similar in each stage between the two groups. 
However, when HCC was associated with cirrhosis of the liver, 
the survival rates after TX were significantly better than those 
after HX at each stage of pTNM classification. The tumor-re-
currence rate was high both after HX (50%) and TX (43%), 
particularly in advanced stages ofpTNM classification (60% or 
more). Twelve patients after HX and 13 patients after TX lived 
more than 5 years during this 10-year period. Fibrolamellar HCC 
and early stages of HCC were highly represented among the 
long-term survivors. Further improvement in survival rates de-
pends on nonsurgical anti-cancer therapy before and/or after 
surgical removal of HCe. 
L IVER TRANSPLANT A nON HAS been widely ac-cepted as a useful therapy for various advanced 
liver diseases. 1-3 However its role in the treatment 
of hepatobiliary malignancy still remains to be deter-
mined.4- 15 Our earlier reports4- 7 and those of others8- 11 
have emphasized the high recurrence rate of hepatocellular 
carcinoma (HCC) in patients treated with liver transplan-
tation, but they also recognized a handful of patients who 
were apparently cured of their malignancy by hepatic re-
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placement. The same is true with conventional subtotal 
hepatic resection. 16-30 
In this study we compared the results obtained by liver 
transplantation to those achieved by subtotal hepatic re-
section among our own series of 181 patients with HCC 
according to the pTNM staging. The prognostic factors 
other than those included in pTNM staging were also ex-
amined for their significance. 
Materials and Methods 
During the lO-year period between 1980 and 1989, 76 
patients with HCC were treated by subtotal hepatic re-
section (HX) and additional 105 patients by orthotopic 
liver transplantation (TX) under cyclosporine-steroid im-
munosuppressive therapy at the University of Colorado 
Health Sciences Center (1980), and at the University 
Health Center of Pittsburgh (1981 to 1989). 
Liver transplantation was used if subtotal hepatic re-
section was not anatomically feasible due to extensive in-
trahepatic involvement of malignancy, or if the underlying 
liver disease and/or hepatic failure precluded this possi-
bility. One third of the patients in the transplant group 
had anatomically unresectable HCC in the normal liver, 
one third had functionally unresectable HCC in the cir-
rhotic liver, and one third had misdiagnosed HCC in the 
failing liver. The extent of HCC was staged using the 
pTNM classification proposed by the International Union 
Against Cancer and the American Joint Committee on 
Cancer (Table 1).31,32 
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TABLE l. pTNM Pathologic Classifications 
Classification 
Stage I TI NO 
Stage II T2 NO 
Stage III TI NI 
T2 NI 
T3 NO, NI 
Stage IVA T4 AnyN 
Stage IVB AnyT AnyN 
TI: Solitary, ,;;2 em, without vascular invasion. 
T2: Solitary, ,;;2 em, with vascular invasion. 
Multiple, one lobe, ,;;2 em, without vascular invasion. 
Solitary, >2 em, without vascular invasion. 
T3: Solitary, >2 em, with vascular invasion. 
MO 
MO 
MO 
MO 
MO 
MO 
MI 
Multiple, one lobe, >2 em, with or without vascular invasion. 
T4: Multiple, > one lobe. 
Invasion of major branch of portal or hepatic veins, 
Nl: Regional 
M 1: Distant metastasis. 
Subtotal Hepatic Resection Group (HX Group) 
There were 76 patients in this group; 53 were male and 
23 were female. The ages ranged from 9 to 86 years with 
a mean ± standard deviation (SD) of 51.4 ± 17.4 years. 
Seventeen of seventy-six patients had associated cirrhosis 
of the liver. Eight patients were chronic carriers of hepatitis 
B surface antigen (HBsAg), and three others had hepatitis 
B surface antibody and/or core antibody (HBsAb and/or 
HBcAb). 
These 76 patients with HCC were stratified according 
to the pTNM classification and are shown in Table 2. 
Twelve of seventy-six HCCs were those of fibrolamellar 
variant (FL-HCC). 
The follow-up periods of this group of patients ranged 
from 16 to 131 months, with a median follow-up of 53 
months as of February 1, 1991. 
Liver Transplantation Group (TX Group) 
There were 105 patients in this group; 70 were male 
and 35 were female. The ages ranged from 3 to 69 years, 
with a mean ± SD of 43.5 ± 18.2 years. Seventy-one of 
TABLE 2. pTNM Stages of76 Patients with Hepatocellular Carcinoma 
Treated by Subtotal Hepatic Resection 
Number of 
Patients Number of Patients 
pTNM 
Stage Total HCC Non-FL FL 
I 0 0 0 
II 19 16 3 
III 25 18 7 
IV-A 32 30 2 
Total 76 64 12 
HCC, hepatocellular carcinoma; FL, fibrolamellar HCC. 
one hundred five patients had associated cirrhosis of the 
liver. Twenty-three patients were chronic carriers of 
HBsAg and 11 others had HBsAb and/or HBcAb. 
These 105 patients with HCC were stratified according 
to the pTNM classification and are shown in Table 3. Ten 
of one hundred five patients had FL-HCC. 
The follow-up periods of this group of patients ranged 
from 16 to 131 months, with a median follow-up of 37 
months as of February 1, 1991. 
Prognostic Factors 
The variables included in pTNM classification (Table 
1) were examined individually for their influence on sur-
vival rates before grouping into the stages. Other variables 
examined were (1) associated cirrhosis, (2) HBsAg, (3) 
microscopic tumor margin, (4) shape of the tumor(s) (cir-
cumscribed versus infiltrative), and (5) fibrolamellar vari-
ant. All variables examined are listed in Table 7. 
Statistical Analysis 
Actuarial survival rates were calculated by the life-table 
method using the BMDP statistical software (University 
of California Press, Berkeley, CA). Statistical comparisons 
across different groups were made by the method of Man-
tel-Cox for univariate analysis. The Cox proportional 
hazards regression model was used to assess the relative 
prognostic importance of factors in predicting survival 
(multivariate analysis). Differences were considered sig-
nificant if the probability value was less than 0.05. 
Results 
Survival Rates 
Overall survival rates of the subtotal hepatic resection 
group (HX group) and those of the liver transplantation 
group (TX group) are shown in Figure 1 and Tables 4 
and 5. There was no difference in the survival rates be-
tween the two groups. 
In the HX group the survival rates of patients with FL-
HCC were significantly (p = 0.016) higher than those of 
TABLE 3. pTNM Stages of 105 Patients with Hepatocellular 
Carcinoma Treated by Liver Transplantation 
Number of 
Patients Number of Patients 
pTNM 
Stage Total HCC Non-FL FL 
I 4 4 0 
II 19 17 2 
III 23 23 0 
IV-A 59 51 8 
Total 105 95 10 
HCC, hepatocellular carcinoma; FL, fibrolamellar HCC. 
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FIG. I. Overall survival rates of patients with hepatocellular carcinoma. 
HX, subtotal hepatic resection; TX, liver transplantation. 
patients with nonfibrolamellar hepatocellular carcinoma 
(non-FL-HCC) (Table 4). In the TX group, however, the 
survival rates were quite similar between them (Table 5) 
because 8 of the 10 patients were in stage IV-A (Table 3). 
The survival rates of patients with FL-HCC tended to 
be higher in the HX group than in the TX group, but 
the difference was not sta.tistically significant (Tables 4 
and 5). 
When HCC was associated with cirrhosis of the liver, 
the survival rates were significantly (p = 0.001) lower than 
those without cirrhosis in the HX group (Table 4), but 
the survival rates were similar in the TX group (Table 5). 
The survival rates of the HX group were significantly (p 
= 0.02) lower than those of the TX group when HCC was 
associated with cirrhosis of the liver, but they were similar 
when HCC was not associated with cirrhosis (Tables 4 
and 5). There was no 4-year survivor after subtotal hepatic 
resection (HX) among the patients with HCC in the cir-
rhotic liver, but the 5-year survival rate after transplan-
tation (TX) was 40.7%. 
The overall survival rates were stratified by the pTNM 
stages and are shown in Tables 4 and 5. Both in the HX 
group and in the TX group the pTNM stages correlated 
well with the survival rates. In both groups the survival 
rates of stage IV-A patients were significantly (p < 0.05) 
lower than those of other stages. There was no statistically 
significant difference in the survival rates when they were 
compared in the same pTNM stages between the HX 
group and the TX group (Table 4 and 5). However, when 
the survival rates of patients with HCC in the cirrhotic 
liver were compared in the same stages, the survival rates 
of the TX group were significantly (p < 0.05) better than 
those of the HX group (Table 6). The difference was most 
striking in stage III. 
Prognostic Factors 
Univariate analyses of five factors included in the 
pTNM classification and six others were performed by 
the Mantel-Cox test and the results were summarized in 
Table 7, with mean survival rates in months. The poor 
prognostic factors of statistical significance both in the 
TABLE 4. Survival Rates After Subtotal Hepatic Resection for Hepatocellular Carcinoma 
Total HCC 
(n = 76) 
FL-HCC 
(n = 12) 
Non-FL-HCC 
(n = 64) 
Cirrhosis 
(n = 17) 
Noncirrhosis 
(n = 59) 
TNM Stage I 
(n = 0) 
TNM Stage II 
(n = 19) 
3 months 
82.9% 
(63) 
100% 
(12) 
79.7% 
(51) 
64.7% 
(II) 
88.1% 
(52) 
100% 
(18) 
6 months I year 
77.6% 71.1% 
(59) (54) 
100% 100% 
(12) (12) 
73.4% 65.6% 
(47) (42) 
47.1% 35.3% 
(8) (6) 
86.4% 81.4% 
(51) (48) 
100% 100% 
(18) (18) 
2 years 3 years 
55.0% 47.2% 
(36) (26) 
83.3% 83.3% 
(9) (9) 
49.7% 40.2% 
(27) (17) 
23.5% 5.9% 
(4) (I) 
64.3% 60.2% 
(32) (25) 
84.2% 78.6% 
(\ 5) (13) 
4 years 
37.2% 
(17) 
64.8% 
(6) 
32.1% 
(II) 
0 
(0) 
49.5% 
(17) 
58.2% 
(8) 
5 years 
32.9% 
(12) 
64.8% 
(5) 
26.3% 
(7) 
43.7% 
(12) 
43.7% 
(4) 
TNM Stage III 
(n = 25) 
80.0% 80.0% 76.0% 68.0% 53.4% 46.8% 46.8% 
TNM Stage IV-A 
(n = 32) 
(20) 
78.1% 
(25) 
(20) (19) 
65.6% 53.1% 
(21) (17) 
(14) (9) (6) (5) 
26.9% 22.4% 16.8% 16.8% 
(7) (4) (3) (3) 
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TABLE 5. Survival Rates After Liver Transplantation/or Hepatocellular Carcinoma 
3 months 6 months 1 year 2 years 3 years 4 years 5 years 
Total HCC 85.7% 74.3% 65.7% 49.0% 39.2% 35.6% 35.6% 
(n = 105) (90) (78) (69) (45) (26) (16) (13) 
FL-HCC 90.0% 90.0% 80.0% 70.0% 50.0% 37.5% 37.5% 
(n = 10) (9) (9) (8) (2) (4) (3) (3) 
Non-FL-HCC 85.3% 72.6% 64.2% 46.8% 38.3% 36.5% 36.5% 
(n = 95) (81) (69) (61) (38) (22) (13) (10) 
Cirrhosis 84.5% 71.8% 63.4% 48.6% 42.9% 40.7% 40.7% 
(n = 71) (60) (51 ) (45) (28) (21) (12) (10) 
Noncirrhosis 88.2% 79.4% 70.6% 50.0% 32.5% 26.0% 26.0% 
(n = 34) (30) (27) (24) (16) (6) (4) (3) 
TNM Stage I 75.0% 75.0% 75.0% 75.0% 75.0% 75.0% 75.0% 
(n = 4) (3) (3) (3) (3) (2) (2) (2) 
TNM Stage II 84.2% 84.2% 79.0% 68.4% 68.4% 68.4% 68.4% 
(n = 19) (16) (16) (15) (12) (12) (8) (5) 
TNM STage III 87.0% 78.3% 78.3% 59.8% 59.8% 52.3% 52.3% 
(n = 23) (20) (18) (18) (11 ) (8) (4) (4) 
TNM Stage IV-A 86.4% 69.5% 55.9% 36.6% 16.3% 10.9% 10.9% 
(n = 59) (5\) (41 ) (33) (15) (4) (2) (2) 
HX group and in the TX group were (1) multiple gross of tumor and lymph node metastasis were significantly 
tumors, (2) vascular invasion, (3) advanced pTNM stages, poor prognostic factors in the TX group, but they were 
(4) positive surgical margin, and (5) infiltrative shape of not significant in the HX group. Fibrolamellar histology 
tumor. was a significantly good prognostic factor in the HX group. 
The tumor size of more than 2 cm was a significantly The fibrolamellar patients had a higher survival rate in 
poor prognostic factor in the TX group, but it could not the TX group for the first 3 years, but this factor was not 
be examined in the HX group because there was no tumor statistically significant because 8 of the 10 patients with 
measuring 2 cm or less in this group. Bilobar involvement this tumor were classified as stage IV-A. Associated cir-
TABLE 6. Survival 0/ Patients with Hepatocellular Carcinoma in the Cirrhotic Liver 
3 months 6 months 1 year 2 years 3 years 4 years 5 years 
HX Group 
Stage I 
(n = 0) 
Stage II 100% 100% 100% 50.0% 50.0% 0% 
(n = 2) (2) (2) (2) (1) (1 ) (0) 
Stage III 60.0% 60.0% 40.0% 40.0% 0% 
(n = 5) (3) (3) (2) (2) (0) 
Stage IV-A 60.0% 30.0% 20.0% 0% 
(n = 10) (6) (3) (2) (0) 
TXGroup 
Stage I 75.0% 75.0% 75.0% 75.0% 75.0% 75.0% 75.0% 
(n = 4) (3) (3) (3) (3) (2) (2) (2) 
Stage II 81.3% 81.3% 81.3% 75.0% 75.0% 75.0% 75.0% 
(n = 16) (13) (13) (13) (11) (11) (7) (5) 
Stage III 89.5% 79.0% 79.0% 56.1% 56.1% 48.1% 48.1% 
(n = 19) (17) (15) ( 15) (8) (7) (3) (3) 
Stage IV-A 84.4% 62.5% 43.8% 26.2% 0% 
(n = 32) (27) (20) (14) (6) (0) 
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TABLE 7. Univariate Analysis of Prognostic Factors (Mean Survival in Months (± SEj) 
Subtotal Hepatic 
Factor Resection Liver Transplantation 
Size of Tumor 
:,,;2cm 
>2cm 51.7 ± 6.6 
Number of Gross Tumor p = 0.0004 
Single 65.5 ± 8.5 
Multiple 25.1 ± 6.1 
Lobar Involvement p = 0.2916 
Unilobar 41.3 ± 7.8 
Bilobar 60.2 ± 9.7 
Vascular Invasion p = 0.0000 
None (VO) 67.1 ± 11.6 
Microscopic (V 1) 51.8 ± 9.7 
Macroscopic (V2) 28.1 ± 9.2 
Lymph Node Metastasis p = 0.6188 
Absent (NO) 52.7 ± 6.8 
Present (N I) 28.0 ± 7.2 
pTNM Stage p = 0.0069 
I 
II 64.0 ± 12.6 
III 57.0 ± 10.6 
IV-A 34.0 ± 8.7 
Histological Type p = 0.0277 
Fibrolamellar 84.9 ± 15.8 
Nonfibrolamellar 42.9 ± 6.5 
Associated Cirrhosis p = 0.0000 
Present 11.4 ± 3.0 
Absent 64.6 ± 7.9 
Microscopic Margin p = 0.0293 
Positive 29.3 ± 11.2 
Negative 57.7 ± 7.6 
HBsAg p = 0.0097 
Positive 17.1 ± 6.8 
Negative 56.9 ± 7.2 
Size of Uninodular Tumor p = 0.1423 
:,,;5cm 26.0 ± 7.2 
>5cm 69.4 ± 9.1 
Shape of Tumor p = 0.0000 
Circumscribed 63.1 ± 8.0 
Infiltrative 17.3 ± 5.4 
* The difference between the HX group and the TX group is statistically 
significant (p < 0.05). 
rhosis ofthe liver and chronic HBsAg carrier status were 
significantly poor prognostic factors in the HX group but 
they were not significant in the TX group. 
Multivariate analysis of prognostic factors that reached 
statistical significance in univariate analysis (p < 0.05) 
revealed that associated cirrhosis and infiltrative shape of 
tumor were independently significant factors of poor sur-
vival in the HX group. In the TX group, bilobar involve-
ment, microscopically positive tumor margin, lymph node 
metastasis, and vascular invasion were independently as-
sociated with poor survival rates. 
p = 0.0241 
(n = 0) 76.4 ± 14.8 (n = 12) 
(n = 76) 40.4 ± 5.2 (n = 93) 
p = 0.0143 
(n = 46) 68.6 ± 10.3 (n = 29) 
(n = 30) 37.9 ± 5.5 (n = 76) 
p = 0.0003 
(n = 44) 66.1 ± 7.8 (n = 51) 
(n = 32)* 28.0 ± 5.2 (n = 54) 
p = 0.0002 
(n = 24) 73.2 ± 10.1 (n = 30) 
(n = 30) 43.3 ± 7.1 (n = 37) 
(n = 22) 21.6 ± 5.6 (n = 38) 
p = 0.0054 
(n = 72) 49.7 ± 5.4 (n = 96) 
(n = 4)* 10.5 ± 3.7 (n = 9) 
p = 0.0015 
(n = 0) 81.1 ± 23.2 (n = 4) 
(n = 19) 70.0 ± 13.2 (n = 19) 
(n = 25) 53.7 ± 9.6 (n = 23) 
(n = 32) 26.5 ± 5.3 (n = 59) 
p = 0.7023 
(n = 12) 51.4 ± 14.4 (n = 10) 
(n = 64) 47.5 ± 5.5 (n = 95) 
p = 0.6450 
(n=17)* 50.0 ± 6.4 (n = 71) 
(n = 59) 39.0 ± 7.6 (n = 34) 
p = 0.0042 
(n = 14)* 10.7 ± 3.9 (n = 9) 
(n = 62) 49.9 ± 5.5 (n = 96) 
p = 0.3183 
(n = 8) 30.4 ± 6.3 (n = 23) 
(n = 68) 49.6 ± 5.9 (n = 82) 
p = 0.0034 
(n = 6)* 89.6 ± 12.4 (n = 18) 
(n = 40)* 28.1 ± 9.8 (n = ll) 
p = 0.0010 
(n = 58) 57.2 ± 6.4 (n = 70) 
(n = 18) 21.8 ± 7.5 (n = 32) 
SE, standard error. 
Tumor Recurrence and Cause of Death 
The recurrence ofHCC was confirmed in 38 (50%) of 
the 76 patients in the HX group and in 45 (42.9%) of the 
105 patients in the TX group during the follow-up period. 
Although overall incidence of tumor recurrence was sim-
ilar for the HX group and the TX group, the HCCs of 
stages II and III recurred more frequently (p = 0.003) in 
the HX group than in the TX group (Table 8). The in-
cidence oftumor recurrence in stage IV-A was extremely 
high: 59.4% in the HX group and 67.8% in the TX group. 
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Forty-eight (63.2%) of the 76 patients in the HX group 
and 67 (63.8%) of the 105 patients in the TX group died 
during the follow-up period. Approximately two thirds of 
deaths were directly or indirectly related to the tumor 
recurrence, both in the HX group and the TX group. It 
is worth noting that tumor-related death among patients 
with HCC of stages II and III was significantly (p = 0.013) 
more frequent in the HX group than in Tx group (Table 
8). Tumor-related death was quite frequent among pa-
tients with stage IV -A tumor both in the HX group 
(53.1%) and the TX group (64.4%) (Table 8). 
Approximately one fifth of the patients in the HX group 
and in the TX group died of various complications of 
hepatic resection or transplantation that were not related 
to tumor recurrence (Table 8). 
Five-year Survivors 
There were 25 patients who survived for 5 years: 12 in 
the HX group and 13 in the TX group (Table 9). None 
of the twelve 5-year survivors in the HX group had as-
sociated cirrhosis of the liver, but 10 of the 13 5-year 
survivors in the TX group had HCCs that developed in 
the cirrhotic liver. Five of the twelve patients in the HX 
group and 3 of the 13 patients in the TX group had FL-
HCC, which was highly represented among the long-term 
survivors. 
Of the 25 patients surviving 5 years, 2 patients had 
stage I tumors, 9 patients each had stage II or stage III 
tumors, and 5 patients had stage IV-A tumors. Three of 
the five patients with stage IV-A tumors had FL-HCC and 
the remaining two patients had nonfibrolamellar HCC, 
both of whom were in the HX group. There was no 5-
year survivor in the TX group who had nonfibrolamellar 
HCC (non-FL-HCC) of stage IV-A disease. 
Discussion 
The results of various therapies for HCC have rarely 
been reported using a universal staging system such as 
the TNM classification. 1 1,14,33 Thus the sensible compar-
isons of results among various therapies and among dif-
ferent reports have been very difficult. To compare our 
results of subtotal hepatic resection for HCC to those of 
liver transplantation, our patients were stratified according 
to their pTNM stage.31 ,32 As shown in Tables 4 to 7, the 
pTNM staging has proved useful in predicting the survival 
rates after hepatic resection (p = 0.0069) and liver trans-
plantation (p = 0.0015). Although all of the variables in-
cluded in the TNM staging are significant prognostic fac-
tors (Table 7), the multivariate analysis of these factors 
among our patients revealed that macroscopic vascular 
invasion, lymph node metastasis, and bilobar distribution 
of the tumor(s) were independently significant among 
them in predicting the survival rates. 
The factors other than those included in the TNM clas-
sification were also valuable in predicting prognosis of 
HCC (Table 7) as reported by others, 18-30 Our study con-
firms that associated cirrhosis of the liver and infiltrative 
shape of the tumor were independently significant in pre-
dicting the poor survival rates after subtotal hepatic re-
section and liver transplantation. Although the survival 
rates of patients with HCC were significantly lower than 
those without malignancy after liver transplantation, I-II 
they were quite similar to those after subtotal hepatic re-
section in each stage of the pTNM classification (Tables 
4 and 5). However, when the patients had HCC in the 
cirrhotic liver, the survival rates after liver transplantation 
were significantly higher than those after subtotal hepatic 
resection in each stage (Table 6). 
Our overall survival rates after subtotal hepatic resection 
for HCC (67.1% at 1 year, 47.2% at 3 years, and 32.9% 
TABLE 8. Tumor Recurrence and Causes of Death 
Number of Patients 
Recurrence Death With Death Without 
of Tumor Tumor Tumor 
HXGroup 
Stage II (n = 19) 10 (52.6%) 8 (42.1%) 2 (10.5%) 
Stage III (n = 25) 9 (36.0%) 7 (28.0%) 6 (24.0%) 
Stage IV-A (n = 32) 19 (59.4%) 17(53.1%) 7 (21.9%) 
Total (n = 76) 38 (50.0%) 32 (42.1 %) 15 (19.7%) 
TXGroup 
Stage I (n = 4) 0(0%) 0(0%) I (25,0%) 
Stage II (n = 19) I (5.3%) I (5.3%) 6(31.6%) 
Stage III (n = 23) 4 (17.4%) 3 (13.0%) 8 (24.8%) 
Stage IV-A (n = 59) 40 (67.8%) 38 (64.4%) 10 (16.9%) 
Total (n = 105) 45 (42.9%) 42 (40%) 25 (23.8%) 
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TABLE 9. List of25 Five-Year Survivors (12 in HX group and 13 in TX group) 
Age/Sex Histology Cirrhosis 
HX Group 
1 9/M FL NO 
2 63/M NON-FL NO 
3 43/F NON-FL NO 
4 14/M FL NO 
5 40/F NON-FL NO 
6 39/M FL NO 
7 33/M FL NO 
8 40/M FL NO 
9 41/F NON-FL NO 
10 65/F NON-FL NO 
II 50/M NON-FL NO 
12 62/M NON-FL NO 
TX Group 
13 26/M FL NO 
14 47/F NON-FL YES 
15 3/F NON-FL YES 
16 7/F NON-FL YES 
17 22/F NON-FL YES 
18 23/F FL NO 
19 4/F NON-FL YES 
20 8/F NON-FL YES 
21 3/F NON-FL YES 
22 9/M NON-FL YES 
23 48/F NON-FL YES 
24 42/M FL YES 
25 33/F NON-FL NO 
at 5 years) were similar to or even slightly better than 
those reported by others.17- 30 However our survival rates 
after hepatic resection for HCC in the cirrhotic liver were 
significantly lower than those reported from Asia, where 
early stages ofHCC were removed from the cirrhotic liver 
by limited hepatic resection.21- 30 Our overall survival rates 
after liver transplantation for HCC in the cirrhotic liver 
(63.4% at 1 year, 42.9% at 3 years, and 40.7% at 5 years) 
were higher than those after hepatic resection for HCC in 
Asia.21- 30 Our survival rates after liver transplantation for 
HCC Of Stages I and II (early stages) in the cirrhotic liver 
were 80% at 1 year and 75% at 3 and 5 years (Table 6). 
A meaningful comparison could not be made in our own 
patients because there were only two patients with HCC 
of stage II in the cirrhotic liver who underwent subtotal 
hepatic resection. However these survival rates were sim-
ilar to or even better than those after hepatic resection 
for most favorable lesions in Asia,26-30 although the hepatic 
functions were worse in the liver transplantation group 
than in the resection group. 
It is impractical and even fraudulent to recommend 
that all HCCs in the cirrhotic liver should be treated by 
liver transplantation. It is equally incorrect to exclude the 
patients with HCC from liver transplantation when the 
malignancy is confined to the liver. The treatment of 
choice for HCC confined to the liver is subtotal hepatic 
resection when it is anatomically and functionally feasible. 
TNM Stage Recurrence Survival 
II No Alive after II years 
IV-A No Alive after 10 years 
III No Alive after 9 years 
III No Alive after 8 years 
IV-A Yes Alive after 7 years 
III Yes Died after 7 years 
IV-A No Alive after 7 years 
III No Alive after 7 years 
III No Alive after 6 years 
II Yes Died after 6 years 
II No Alive after 5 years 
II No Alive after 5 years 
IV-A No Alive after 9 years 
II No Alive after 9 years 
II No Died after 7 years 
I No Alive after 8 years 
III No Alive after 8 years 
IV-A Yes Died after 6 years 
I No Alive after 7 years 
II No Alive after 6 years 
III No Alive after 6 years 
II No Alive after 6 years 
III No Alive after 6 years 
II No Alive after 5 years 
III No Died after 5 years 
Liver transplantation is the treatment of choice for HCC 
confined to the liver when the hepatic functions are poor 
and/or the HCC cannot be removed by subtotal hepatic 
resection. 
The HCC recurred in one half of the patients after he-
patic resection and liver transplantation (Table 8). In the 
HCCs of stages II and III, the tumor recurrence was sig-
nificantly higher after hepatic resection than liver trans-
plantation. The fact may indicate either that the staging 
was less accurate in the hepatic resection group because 
only a removed part of the liver could be examined 
pathologically or that new HCC developed in the retained 
portion of the liver after hepatic resection. Nevertheless 
a relatively low incidence of tumor recurrence after liver 
transplantation for HCC of stages II and III were en-
couraging. On the other hand, two thirds ofHCCs in stage 
IV -A recurred after hepatic resection and liver transplan-
tation (Table 8). 
Further improvement in survival rates will be achieved 
in some degree by reducing the incidence of early death 
from surgical complications, but the major progress will 
depend on nonsurgical anti-cancer therapy. For this series 
of our patients, organized plans of anti-cancer therapy 
before and/or after surgery were not available. Because 
the introduction of a novel immunosuppressive drug, FK 
506, to our liver transplantation in mid 1989,34,35 we have 
been exploring the possible beneficial effects of neoadju-
----------------------------
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vant and adjuvant therapy for primary h~patobiliary ma-
lignancy. The improvement may be expected with this 
approach, particularly in HCCs of stages II and III after 
hepatic resection and in HCCs of stage IV-A after hepatic 
resection and liver transplantation, in which the tumor 
recurrence is frequent. 
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transplantation for hepatocellular carcinoma that has been previously 
reported. 
May I have that slide, please? As shown here, the 2- and 3-year survival 
in this large group of patients is approximately 30%, and the 5-year 
survival is between 20% and 25%. The data presented today by Dr. Iwat-
suki represent a measurable improvement over this, with a 40% to 50% 
survival at 2 to 3 years and a 36% survival at 5 years. 
What factors have accounted for this benefit? The first that comes to 
mind is that all of the cases reported today were done in a modem area 
of liver replacement in which cyclosporine was the mainstay of immu-
nosuppression, and many of'the technical and management refinements 
of liver transplantation have been codified. Patient selection also could 
playa role. 
This report includes a series of tumors that may have a more favorable 
prognosis: namely, fibrolammelar variant, 10 cases, although as men-
tioned, several of these were of the stage 4A variety; and early lesions, 
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TNMI, stage 1, four cases; and TM stage 2, 19 cases. Although the 
former group, fibrolammellar, did not show a statistically improved sur-
vival, a trend in this direction certainly is apparent at 2 to 3 years. More-
over, stage I and stage 2 lesions behaved similarly to incidental hepa-
tocellular tumors, which are known to have an exceptionally good prog-
nosis after transplantation. 
Notwithstanding the above, the results reported with TNM stage 3 
clearly represent an improvement over previous reports. In fact, 5-year 
survival in this group was 47%, which contrasts with a recent paper by 
Ring et al that reports no patient survival beyond 1 year in the presence 
oflymph node involvement. 
The reason for this difference is not apparent, and thus I would like 
to ask: How many of the stage 3 lesions in the Pittsburgh group were 
T3 NO; in other words, how many had no lymph node involvement? 
Finally it is unlikely that we can achieve much better results from 
surgery alone. In our program all patients with tumors who are transplant 
candidates are enrolled in an adjuvant trial of continuous 5-fluorouracil, 
cisplatin, combination adriamycin therapy for 6 months. Other centers 
have similar protocols. Results up to 3 years have been encouraging. 
Hepatitis-B-infected patients, however, have a high incidence of tumor 
recurrence, which was not reported in the Pittsburgh series. 
Dr. Iwatsuki, you alluded to the use of adjuvant therapy in your 
manuscript. Do you have any further information on this, and how it 
specifically impacts on stage 3 and stage 4A tumors? 
DR. HENRI BISMUTH (Villejuif, France): I agree with the general con-
clusion of the paper, that is, the superiority of transplantation when 
compared with resection, but there are several points I would like to 
raise. 
Over the last 10 years, we have treated 115 patients with cirrhosis and 
hepatocellular carcinoma (HCC), 60 by resection and 55 by orthotopic 
transplantation. We have excluded from this transplant group tumors 
that were incidentally discovered at subsequent histologic examination 
so as only to compare the two groups in which tumor was identified 
preoperatively. 
With respect to the results, we obtained broadly similar figures to 
those of Dr. lwatsuki and the Pittsburg group when we examined the 
resection or transplant group as a whole. That is the 3-year survival was 
slightly better for transplantation (61%) than for resection (50%), but 
was much better, 54% and 24% respectively, when comparing survival 
without recurrence. 
I would like to focus on two further points. When we compared our 
results for transplantation and resection, differences became highly sig-
nificant when looking at single lesions: 74% and 25% 3-year survival 
without, respectively; and also for lesions less than 3 em in size: 65% 
and 12%, respectively, again recurrence free at 3 years. 
These clear advantages for transplantation are considerably reduced 
when we looked at lesions that were multiple or more than 3 em in size. 
So the point may be made by looking at the best and worse cases in 
which transplantation was performed in patients with less than three 
nodules all less than 3 cm in size or more than three nodules where one 
or more was more than 3 em in size. Here the 3-year survival without 
recurrence is 93% and 10%, respectively. Thus in the latter group, the 
survival is comparable for secondaries and for HCC, in which people 
question whether we should transplant at all. 
Although it may be unwise to extrapolate results from European pa-
tients, with HCC mainly occurring against a background of posthepatitic 
(B or C) cirrhosis, to those in America, I would be interested in knowing 
if Dr. Iwatsuki's large experience has led him to notice anything similar, 
especially in view of the fact that our conclusion-that we should be 
transplanting patients that we could resect and not transplanting those 
we cannot resect-superficially seems rather different from his own. 
DR. SHUNZABURO IWATSUKI (Closing discussion): Answering Dr. 
Busuttil's question first, we have only four patients with lymph node 
positive in stage 3. In Hanover group, I believe that they had only six 
patients in stage 3, and that their survival is lower than ours. There are 
heterogenous patients in stage 3; lymph node positive and lymph node 
negative. TNM stage is useful, but if you read the rules of staging, there 
are still a lot of defects in the staging. 
But in the past, we always presented the data of liver transplantation 
or hepatic resection without using any common ground of classification. 
The incidental tumor in Japan may be less than 2 cm, but in the United 
States, even a 5-cm lesion can be missed. 
And with regard to adjuvant chemotherapy, we have been using a 
new adjuvant chemotherapy for hepatomas. We lose some patients be-
cause of the complications of chemotherapy, but we may gain some in 
long-term survival. The results are not in yet. 
Answering Dr. Bismuth's questions of single tumor ofless than 5 cm. 
If you treat this with liver transplantation, the survival rate is good. But 
if one can do the resection safely, there is no reason to transplant. There 
is a shortage of organs, and I think first choice of treatment for hepatoma 
or any tumor of the liver is subtotal resection. 
Of course if we do the liver transplantation for a small tumor, the 
results are better, but there is no reason to do that. Liver resection can 
achieve the same result if the patient can tolerate the resection. The 
patients with a small tumor and with poor liver function tests should 
have transplants, not for cancer, but for the hepatic insufficiency. 
